Obesity Type Articles & Analysis
28 news found
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
Effects of finerenone in patients with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability and duration of diabetes Short Oral Discussion Area 8 September 22, 2022; 12:00 – 1:00pm (CEST) Further data from FIDELITY will investigate the efficacy and safety of Kerendia in CKD and T2D patients with ...
ByBayer AG
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic ...
“This collaboration brings together two leading, diverse technological platforms and teams for the discovery of novel consumer products that may have therapeutic benefits for type 2 diabetes and obesity,” said Jay Galeota, president and CEO, Kallyope. ...
Both studies demonstrate the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity. “In these analyses, the data highlight clinically significant reductions in HbA1c showing 1.3% absolute mean reduction Worldwide and a 1.9% mean reduction in the UK, even though there were many patients without diabetes ...
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive ...
About Diabetic Nephropathy Diabetic nephropathy (DN) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive ...
Orlistat is a drug designed to treat obesity. The main function of Orlistat is to prevent the absorption of fat from the diet in humans. ...
” Over the past 13 months, Kallyope has advanced four compounds into the clinic in its two lead programs in Type 2 diabetes, obesity, and diseases of the gastrointestinal barrier. ...
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, ...
These are the start-ups that most impressed Britain’s top entrepreneurs and investors in 2019. There was a technology theme to the selections, while several on our panel of small business champions picked companies, they claimed were tackling some of the world’s biggest problems by treating Alzheimer’s disease and broadening access to education. ...
The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. Novo Nordisk expects to initiate clinical development of the ...
” Whether pinpointing veins for IVs, evaluating cardiological conditions or scanning the lungs of COVID-19 patients, Exo’s powerful device will aim to see deeper and provide more accurate imaging for a wide range of body types, including obese and overweight patients that are hard to scan effectively with current handheld ultrasound technology. ...
ByExo
Abnormal blood lipid levels are usually associated with various diseases, such as hypertension, coronary arteries, hypothyroidism, type 2 diabetes, obesity, pancreatitis, etc. Creative Enzymes provides a variety of enzyme products related to blood lipids from different sources to help you in your research. ...
“COVID-19 patients with pre-existing conditions such as obesity and type 2 diabetes suffer three to four times higher mortality rate than the average patient population,” said Zhao, professor and Eveleigh-Fenton Chair of Applied Microbiology of the Department of Biochemistry and Microbiology at the School of Environmental and Biological Sciences. ...
“I am excited and honored to join the talented team at GI Dynamics. Type 2 diabetes and associated comorbidities, including obesity, impact almost 500 million people around the globe. ...
(‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), the Company’s majority ...